News

The study, initiated in September 2008, was a blinded, placebo-controlled study in 32 healthy volunteers which studied multiple ascending doses up through the highest planned dose of 1800mg.

The application for the marketing authorization for nimotuzumab was submitted to the European Medicines Agency on October 4, 2007. At the time of the withdrawal it was under

The preliminary analysis of the safety data showed that the combination of four drugs was generally well tolerated in patients who had received no prior therapies and response

According to the company, patients receiving Promacta were eight times more likely than those on placebo to maintain platelet counts between 50,000 to 400,000/microliters during a six-month treatment

No new safety signals were observed in either of these studies and the safety profile was consistent with previous experience with Rituxan, the company said. In CLL8, patients

The reported data are from a Phase I trial of XL019 in patients with advanced primary myelofibrosis, or with advanced myelofibrosis occurring post-polycythemia vera or post-essential thrombocythemia. This

The objective of the multinational study was to assess the safety of four dose regimens of DU-176b in patients with non-valvular atrial fibrillation (AF), as compared to warfarin.

The Phase III global study will compare DU-176b with warfarin in preventing stroke and systemic embolic events in patients with atrial fibrillation. The primary safety assessment will be

The CE-marked Signature LTx v2.0 is a qualitative in vitro diagnostic (IVD) device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from